Triad of Trouble: A case of joint, skin and GI woes Sara Faghihi Kashani, MD, presents her poster at RWCS 2023. https://t.co/Y7YbgqbfzY https://t.co/EX1kTIiSRt

• https://bit.ly/3KdCuNd

#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/E74Qovuk0m https://t.co/vTAfWu0lta

• https://bit.ly/3ntMSrz

"My eye is swollen": an underrecognized mimic of IgG4-related disease Artem Minalyan, MD, presenting his poster at RWCS 2023. https://t.co/9Dd8A9yry1 https://t.co/C0hgLV2r2W

• https://bit.ly/3Ke8JMp

Updated AAV Treatment Recommendations AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include GPA, microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). https://t.co/gQr92GpE5j https://t.co/SGDh1uNg2b

• https://bit.ly/3ngjnsT

Study of 3804 runners from 2019, 2021 Chicago marathon looked at assocn betw marathons running and arthritis. Prevalence of hip / knee arthritis was 7.3%. Hip/Knee OA was assoc w/ prior injury/surgery, older age, FamHx, & BMI (not #marathons, mileage) https://t.co/P91dR9kSgY https://t.co/p7hFKEbGOw

• https://bit.ly/3LYOYtt

Autoimmune-Rheum Dz (AIRD) flares occur in 10% w/ COVID vaccination, esp in pts w/ comorbidities, autoimmune morbidities & mental health disorders & Moderna vaccine. 3453 AIRD pts who recv Vax 9.5-11.3% had clinical flares (Arthritis 62% & fatigue 59%) https://t.co/RCtQnA9vc9 https://t.co/G5cXukkpUB

• https://bit.ly/3nnYfBh

Anti-mesangial autoantibodies in IgA nephropathy IgA nephropathy (IgAN) is a kidney disorder characterized by the buildup of immunoglobin A (IgA) in the glomeruli, which are bundles of capillaries that filter blood in the kidney. https://t.co/owOoAMrtxW https://t.co/RZMGkagcWJ

• https://bit.ly/3lMgoIq

Tofacitinib May Reduce Interstitial Lung Disease Risk in RA Tofacitinib (Xeljanz) in patients with RA stood out among several other biologic and targeted sDMARDs when it came to the incidence of ILD, a retrospective cohort study showed. https://t.co/XKjuxLWAKH https://t.co/M7ri9AL2wH

• https://bit.ly/3Zm4Jxw

What to do about pre-clinical RA? Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA. https://t.co/k8LcTmlpZs https://t.co/NBBbi91Fbi

• https://bit.ly/40w6JVH

Our old friend, hydroxychloroquine Dr.Arnaud ( @Lupusreference ) took the time to review one of our oldest therapies: hydroxychloroquine. He outlined how the anti-malarial medication has efficacy and widespread usage in lupus. https://t.co/NJK7uJIqsV https://t.co/CQStRUUkUn

• https://bit.ly/3JOlxHQ

#RNL2023 Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/Ej0Rm2VFCk https://t.co/aiHGE1LsAr

• https://bit.ly/3ZbG12R

#RNL2023:Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/UvXfC2iIEp https://t.co/zBoMiyy056

• https://bit.ly/3JK6nn8

EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). https://t.co/0fXUVv0sCR https://t.co/fT6iAOPOpc

• https://bit.ly/3Kagzqw

LRA announces the 2023 recipients of the Lupus Innovation Award during #NationalKidneyMonth as three of this year’s seven award recipients are studying issues that come with this too-common complication. 🧵1of2 https://t.co/VZL9qJu9kF